Innovative
solutions
in nuclear
medicine

Cyclopharm (ASX:CYC) | Bell Potter Healthcare Conference 2022 Presentation

Cyclopharm (ASX:CYC) | Bell Potter Healthcare Conference 2022 Presentation

We are excited to announce our partnership with Jubilant Radiopharma for the distribution of RUBY-FILL® throughout Europe

Cyclopharm partners with McMaster University to Evaluate Technegas® use and risks of COVID-19

Cyclopharm partners with McMaster University to Evaluate Technegas® use and risks of COVID-19

Lung Imaging and COVID-19 Impact

Lung Imaging and COVID-19 Impact

Read recommendations about Technegas®

Technegas® NDA pending US FDA review

Technegas® NDA pending US FDA review

The Technegas® NDA was accepted by FDA on 26 March 2020. Learn more.

R&D

With over 30 years of experience in the field of nuclear and respiratory medicine, Cyclopharm continues to enhance and develop medical innovations.

About Us

Cyclopharm is a radiopharmaceutical company servicing the global medical community since 1986.

Investor Centre

Cyclopharm Limited (CYC.AX)

Latest Presentation

Our Products

Proprietary radiopharmaceutical technologies designed to improve patient outcomes every day.

Partnerships

With sales to over 60 countries throughout the world, Cyclopharm delivers its products through a range of partnerships.

Copyright © Cyclopharm 2023 | Last Updated: March 8, 2019 Privacy Policy